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The ED-L1E promoter of the LMP 1 gene is a GC box-containing promoter. To test if Sp1/Sp3 are important for modulating
ED-L1E promoter activity through the GC box, site-specific mutation and deletion constructs carrying a reporter gene were
transfected into NPCTW076 and C33A cells. Results showed that deletion or mutation of the GC box abolished ED-L1E
activity. Association of Sp1/Sp3 with the GC box was confirmed by electrophoretic mobility shift and supershift assays using
Sp1- and Sp3-specific antibodies. Transfection of Sp1- and Sp3-expressing vectors into NPCTW076 and Sp-deficient
Drosophila SL2 cells activated ED-L1E in a dose-dependent fashion and showed an additive effect. Data suggest that both
factors may function as transcriptional activators and regulate the ED-L1E promoter in human epithelial cells. © 1999 Academic
PressKey Words: EBV; LMP1; ED-L1E promoter; Sp1; Sp3.
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cINTRODUCTION
Epstein–Barr virus (EBV) is a herpes virus closely as-
ociated with several human malignant diseases, includ-
ng nasopharyngeal carcinoma (NPC) (Desgranges et al.,
975). In NPC cells, EBV infection is latent and only two
iral antigens, EBNA 1 and LMP 1, are expressed (Fahr-
eus et al., 1988). In these cells, the LMP 1 gene is
xpressed from an upstream promoter, ED-L1E, which is
pproximately 500 bp upstream from the putative pro-
oter, ED-L1 (Chang et al., 1997). The latter is preferen-
ially activated in lymphoblastoid cell lines (LCLs) which
re transformed by EBV in vitro. The differential usage of
romoters in different cellular backgrounds indicates
hat cellular factors may play an important role in mod-
lating EBV gene expression. Previous reports indicated
hat the upstream promoter sequence, located within the
erminal repeats of the EBV genome in the C15 se-
uence, contained two GC boxes, I and II (Sadler and
aab-Traub, 1995). Analysis of the minimal promoter se-
uence of ED-L1E derived from NPC strain EBV shows
hat it is a TATA-less and GC-rich promoter (Fig. 1A).
owever, this region did not contain the GC boxes as
escribed in the C15 sequence. The GC box has been
nown to be recognized by cellular factors, Sp family
roteins including Sp1 and Sp3. In this study, we first
etermined the functional GC box within the ED-L1E
romoter with the minimal activity from NPC strain EBV
y analyzing deletion and mutation mutants. We then
1 To whom correspondence and reprint requests should be ad-
fressed. Fax: 886-3-328-5683. E-mail: ysc@mail.cgu.edu.tw.
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288ested if this GC box was associated with Sp1 and Sp3.
inally, we examined if this GC box was regulated by Sp1
nd Sp3.
RESULTS AND DISCUSSION
he 248 to 233 region was essential for ED-L1E
romoter activity
To determine the crucial GC-rich region of ED-L1E pro-
oter derived from NPC strain EBV, plasmid pGL2B2423/
171 (Fig. 1B; same as pGL2B-4KB in Chang et al., 1997)
hich contained minimal promoter activity in NPC cells
as used to generate three deletion mutants, pGL2B257/
88, pGL2B248/174, and pGL2B233/174, respectively
Fig. 1). These plasmids were then transfected into two
pithelial cell lines, C33A and NPCTW076, and the pro-
oter activities were determined by luciferase activity (Fig.
). Results showed that in C33A or NPC cells, the luciferase
ctivities of pGL2B2423/1171, pGL2B257/188, and
GL2B248/174 were about the same. Deletion of the GC-
ich region between 2423 and 248 did not significantly
educe promoter activity. This suggested that although the
423 to 248 region of ED-L1E contained several putative
p1 sites, it was indispensable for ED-L1E promoter activity
n human epithelial cells. In contrast, the deletion of 248 to
33 (pGL2233/174 in Fig. 1B) in the ED-L1E promoter
ould dramatically reduce the promoter activity to a basal
evel in both C33A and NPC cells. Compared to the activity
f pGL2B248/174, that of pGL2B233/174 was almost
ourfold lower in C33A cells and sevenfold lower in NPC
ells (Fig. 2). Thus, the region of 248 to 233 was essentialor promoter activity of ED-L1E in human epithelial cells.
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289EFFECT OF Sp1 AND Sp3 IN REGULATION OF THE ED-L1E PROMOTER OF EBV LMP 1he 248 to 233 region contained a functional
C box
The sequences between 248 and 233 contained the
utative GC box which may be regulated by the family of
p proteins. Thus, to further confirm if the Sp family really
odulated ED-L1E promoter activity, the potential Sp1
inding sequences were site-specifically mutagenized
y PCR. The sequence of the GC box, 59-aaggccacgc-
ccctc-39, was converted to 59-aaggaccagctgcctc-39 (Fig.
A). The plasmid contained the mutated sequence
pGL2B248/174m) (Fig. 1B) and was transfected into
33A and NPC cells and the promoter activity was then
etermined. As shown in Fig. 2, the activity of
FIG. 1. Nucleotide sequence and schematic representation of the
ranscriptional initiation site (11) of ED-L1E is located at nt 170,099, cor
r Sp1 binding site is located between 248 and 233, relative to the tra
9 primers, F257, F248, F248m, and F233, and one 39 primer, R18
onstructs shown in B. (B) ED-L1E promoter constructs pGL2B257/188
257/R188, F248/R188, and F233/R188, respectively, as describedGL2B248/174m was similar to that of the deletion sutant, pGL2B233/174. This indicated that the 248 to
33 region contained the only functional GC box within
he ED-L1E promoter.
p1 and Sp3 bind to the 248 to 233 region as
xamined by electrophoretic mobility shift assay
To evaluate if the Sp1 indeed bound to the GC box, a
el mobility shift assay was performed (Fig. 3). The
robe(257/233) included the region that covered the
otential Sp1 binding site or the GC box (Fig. 3A). It was
9 end labeled with [g-32P]ATP and then incubated with
uclear extracts purified from C33A cells. The products
ere then analyzed on a 4% polyacrylamide gel. As
E promoter. (A) Upstream sequences of the ED-L1E promoter. The
ding to sequences of the EBV genome of the B95-8 strain. The GC box
tion initiation site (11) of ED-L1E. The sequence and positions of four
shown. These primers were used to generate the ED-L1E promoter
74, 248/174, and 233/174 were generated by PCR using primer sets
Materials and Methods.ED-L1
respon
nscrip
8, are
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290 TSAI ET AL.nd b, were formed using probes 257/233 (lane 2).
omplex a disappeared by addition of 100-fold molar
xcess of unlabeled competitor a (lane 3) and competitor
(lane 4), but not by competitor c (lane 5) (Fig. 3B). To
onfirm the presence of Sp proteins in these complexes,
he Sp1- and Sp3-specific monoclonal antibodies were
ncubated with the complexes before being analyzed on
he gel. As shown in Fig. 3B, complex a was supershifted
y incubating nuclear extracts with Sp1-specific antibody
lane 6, supershift I), Sp3-specific antibody (lane 7, su-
ershifts II and III), or a mixture of both antibodies (lane
). Complex b was only abolished by adding 100-fold
olar excess of cold competitor a (lane 3), but not by
nlabeled competitor b or c (lane 4 or 5). Taken together,
hese data indicated that complex a represented the
p1/Sp3–DNA complex, whereas complex b may not be
ssociated with Sp family proteins. Therefore, both Sp1
FIG. 2. Promoter activity of ED-L1E in C33A and NPC cells. (A) DNA
hosphate precipitation method as described under Materials and M
ransfection as recommended by the manufacturer (GIBCO, UK). Promo
he luciferase activity of 25 and 100 mg of cell extracts from C33A and N
as cotransfected with test plasmids. Results shown in this figure we
hown as black lines.nd Sp3 may form a complex with the 248/233 region of tD-L1E and then modulate promoter activity. Judging by
he binding intensity, stronger binding was detected
hen anti-Sp3 antibody was added. This may imply that
p3 binds to this GC box region with higher affinity than
p1 or that this particular Sp3 monoclonal antibody has
higher binding ability than the Sp1 antibody to the
NA–protein complex. Similar results were observed
hen nuclear extracts of NPC cells were used (data not
hown).
dditive effect of Sp1 and Sp3 on the ED-L1E
romoter
To analyze the effect of Sp1 and Sp3 on the ED-L1E
romoter, 1, 3, and 5 mg of Sp1 or Sp3 expression vec-
ors, individually, were cotransfected with pGL2B248/
74 into NPC cells. As determined by luciferase activi-
L1E promoter constructs were transfected into C33A cells by calcium
. (B) Plasmid DNAs were introduced into NPC cells by lipofection–
ivity, as relative light unit (RLU) value, was determined by quantitating
s, respectively. For the internal control, the pSV-b-galactosidase vector
ages of six individual experiments and the standard deviations wereof ED-
ethods
ter act
PC cell
re averies, both Sp1 and Sp3 activated the ED-L1E promoter in
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291EFFECT OF Sp1 AND Sp3 IN REGULATION OF THE ED-L1E PROMOTER OF EBV LMP 1dose-dependent manner in NPC cells (Fig. 4A). The
ame constructs were transfected into SL2 cells that lack
he endogenous Sp1 and Sp3 proteins. We found that
ither Sp1 or Sp3 could also activate the ED-L1E pro-
oter in a dose-dependent manner in SL2 cells. Cotrans-
ection of both Sp1 and Sp3 expression vectors with
GL2B248/174 cells showed an additive effect on the
D-L1E promoter (Fig. 4B).
Previous studies have demonstrated that LMP 1 is a
otential oncogene. Expression of LMP 1 in transgenic
FIG. 3. Interaction of Sp1 and Sp3 with the GC box region within the
A) Sequences between 257 and 216 of the ED-L1E promoter. The re
rom 248 to 233 or the GC box was used as competitor b. The region
ells were reacted with 59 end-labeled oligonucleotide without (lane 2)
p1-specific antibody (lane 6), Sp3-specific antibody (lane 7), and comb
ontaining nuclear extracts and labeled probe. The products were ana
hown in lane 2. Complex a was supershifted by anti-Sp1 antibody toice downregulated the expression of cytokeratins in ipithelial cells and resulted in hyperplasia of the skin
Wilson et al., 1990). It also showed transformation of
odent cells and induction of tumors in nude mice (Chen
t al., 1992). Recent studies reported that LMP 1 derived
rom NPC biopsies was more tumorigenic than that of
he B95-8 strain (Chen et al., 1992). The typical 30-bp
eletion in the C-terminus of LMP-1 was crucial for
rocessing of tumor formation in nude mice (Li et al.,
996). In NPC cells, transcriptional control of the LMP 1
ene in these malignant cells was also distinct from that
promoter as analyzed by electrophoretic mobility shift assay (EMSA).
m 257 to 233 was used as the probe and competitor a. The region
32 to 216 was used as competitor c. (B) Nuclear extracts from C33A
ith (lanes 3, 4, and 5) unlabeled competitors (a, b, and c), respectively.
of these two antibodies (lane 8) were also added to reaction mixtures
n a 4% polyacrylamide gel. Two complexes, a and b, were formed as
hift I and by anti-Sp3 antibody to supershifts II and III.ED-L1E
gion fro
from 2
and w
inations
lyzed on LCLs. The transcript of LMP 1 was 3.7 kb in NPC
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292 TSAI ET AL.iopsies which was initiated from the upstream pro-
oter, ED-L1E, instead of the 2.5-kb transcript which was
erived from the putative ED-L1 promoter (Chang et al.,
997). Regulation of ED-L1 has been known to be mod-
lated by EBNA-2 through mediation of Jk on the EBNA 2
esponsive element (Ling et al., 1993) and was also
nhanced by EBNA 1-mediated FR within the EBV ge-
ome (Gahn and Sugden, 1995). Thus, regulation of ED-
1E must be different from that of ED-L1. The upstream
romoter derived from C15 nude mice-passaged NPC
umor tissue was located within the first terminal repeat
nd was regulated by Sp1 through the two GC boxes,
C-I and GC-II (Sadler and Raab-Traub, 1995). These
FIG. 4. Additive activation of the ED-L1E promoter by Sp1 and Sp3. (A
otransfected with 1, 3, or 5 mg, respectively, of either CMV-Sp1 or CMV
nder Materials and Methods. (B) Effect of Sp1 and Sp3 in SL2 cells
MV-Sp1 and CMV-Sp3 were introduced into SL2 cells following the pr
s vector control and used to bring the total amount of DNA to a final 1
escribed. Results shown in this figure were averages of six individuaequences were not found in the minimal promoter of mD-L1E derived from NPC strain EBV. In our ED-L1E
onstruct, deletion of upstream sequences (2423 to
48) did not affect activity. Instead, the GC box, located
etween 248 and 233, was activated by Sp1 and Sp3,
hich was sufficient for maintaining minimal promoter
ctivity. Sp family proteins contain zinc fingers as well as
lutamine- and serine/threonine-rich amino acid
tretches. The DNA binding domains of these proteins
re highly conserved and they recognize GC boxes with
pecificity and affinity. Many studies have reported that
p1 could activate different cellular and viral promoters,
hile Sp3 had inhibitory functions (see review by Lania
t al., 1997). One of the examples was the HPV-16 pro-
of Sp1 and Sp3 in NPC cells. Two micrograms of pGL2B248/174 was
to NPC cells by calcium phosphate precipitation method as described
ach transfection, 2 mg of pGL2B248/174 and indicated amounts of
e described under Materials and Methods. Plasmid pCMV3 was used
r each transfection. The luciferase assay was performed as previously
iments and the standard deviations were shown as black lines.) Effect
-Sp3 in
. For e
ocedur
0 mg fo
l experoter which has been known as epithelial specific. This
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293EFFECT OF Sp1 AND Sp3 IN REGULATION OF THE ED-L1E PROMOTER OF EBV LMP 1romoter was activated by Sp1, but inhibited by Sp3 as
ested in SL2 cells (Apt et al., 1996). On the other hand,
p3 could function as a transcriptional activator in mam-
alian and SL2 cells (Dennig et al., 1996; Majello et al.,
997). Using ED-L1E promoter constructs as test plas-
ids, we found that both Sp1 and Sp3 activated the
romoter via the same GC box. This finding suggests
hat Sp3 could function as a positive regulator, not an
ntagonist, for Sp1-mediated activation in two human
pithelial cell lines examined in this study. Although it is
enerally believed that Sp1 is ubiquitously expressed,
p1 gene expression can show up to 100-fold differ-
nces in different cell types and different stages of de-
elopment in the mouse (Saffer et al., 1991). ED-L1E is
pecifically active in human epithelial cells and NPC
iopsy tissues (Chang et al., 1997). As determined by
estern blots, the Sp1 level and the Sp3 level were about
he same in these cells (data not shown). Therefore, the
ransactivation of ED-L1E by Sp1 and Sp3 is actively
egulated in these cells. It has been reported that the GC
oxes that can be activated by Sp1 are often found near
inding sites for other transcription factors. This may
llow Sp1 and Sp3 to act in a combinatorial manner with
ther transcription factors. Within the 248 to 233 region
f ED-L1E, there are several potential transcription factor
inding sites, such as STAT (227 to 218, TTCCAGGAA)
nd HSF (222 to 218, GGAAT). Whether these factors
ill interact with Sp1/Sp3 requires further investigation.
Sp1 has been implied in the control of cell cycle-
egulated genes such as thymidine kinase, B-myb, and
ihydrofolate reductase (Karlseder et al., 1996). Sp1 bind-
ng sites appear to play a critical role for the mainte-
ance of the methylation-free CpG island (Brandeis et al.,
994). Thus, it appears that Sp1 plays an active role in
ontrolling putative cell cycle-regulated genes and it is
equired to prevent methylation of CpG islands. Methyl-
tion is one of the regulatory mechanisms that controls
he promoter usage of EBV genes in different cell back-
rounds or latent stages of EBV. Methylation of a partic-
lar CpG site in the EBV promoter (e.g., Cp) inhibits
ormation of a sequence-specific binding complex impor-
ant for transcription (Robertson et al., 1995). In NPC
ells, ED-L1E is a functional promoter and is not meth-
lated. Sp1/Sp3 may bind to the GC box to prevent
ethylation of this region and also to activate this cell
ype-specific promoter.
MATERIALS AND METHODS
ell lines
The two human epithelial cell lines, C33A (ATCC
TB31) and NPCTW076 (or abbreviated as NPC cells),
sed in this study were maintained in DMEM supple-
ented with 10% fetal bovine serum. SL2 cells were
aintained in Schneider insect medium (GIBCO, UK) fupplemented with 10% fetal bovine serum, 50 mg/ml
treptomycin, and 50 mg/ml penicillin.
lasmid construction
The ED-L1E-containing construct, pGL2B2423/1171,
as described before (as pGL2B-4KB in Chang et al.,
997). Plasmids pGL2B257/174, 248/174, and 233/
74 were generated by PCR using primer sets F257/
188, F248/R188, and F233/R188, respectively. PCR
roducts were digested with HinfI and then treated with
lenow fragment before being ligated with the SmaI-
igested pGL2 Basic (Promega, Madison, WI).
GL2B248/174m was generated by PCR using primers
248m (59-aaggaccagctgcctc-39) and R188. The PCR
roduct was inserted into SmaI-digested pGL2 Basic
Promega) after being digested with HinfI. pGL2B257/
88 was constructed by PCR using primer set F257/
188. This blunt-end PCR product was ligated to pGL2
asic to generate pGL2B257/188. PCR was carried out
s described previously (Chang et al., 1997). Sequences
f all constructs were determined by using the T7 Se-
uenase v2.0 DNA sequencing kit (Amersham, UK).
ransfection and reporter gene activity assay
Plasmid DNAs were transfected into C33A cells by
alcium phosphate precipitation method as previously
escribed (Graham and van der Eb, 1973). Five micro-
rams of each plasmid DNA was transfected into 5 3 105
33A cells per well in a six-well dish and cells were
arvested 24 h after transfection. Plasmid DNAs were
ntroduced into NPC cells by lipofection–transfection as
ecommended by the manufacturer (GIBCO, UK). One
icrogram of plasmid DNA was transfected into 1.5 3105
ells per well in a six-well dish and cells were harvested
4 h after transfection. Twenty-five and 100 mg of cell
xtract were applied to assay the luciferase activity for
33A and NPC cells, respectively. For transfection of
NA into SL2 cells, 2 mg of pGL2B248/174 and various
mounts of Sp1- and/or Sp3-expressing vectors were
ntroduced into cells by calcium phosphate precipitation
ethod as described by Di Nocera and Dawid (1983). For
ach transfection assay, vector DNA was added to keep
he final amount of DNA constant. Promoter activity was
etermined by quantitating luciferase activity expressed
rom the transfected plasmids. Luminescence was mea-
ured with Autolumat LB95 (Berthold, Germany) and the
elative light unit (RLU) value was then determined. For
he internal control, the pSV-b-galactosidase vector (Pro-
ega) was cotransfected with test plasmids. b-Galacto-
idase activity at 420 nm was measured with a spectro-
hotometer (Scimadzu UV-160A, Japan). All plasmid
NAs used in transfection were prepared from two cy-
les of a cesium–ethidium bromide gradient ultracentri-uge.
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294 TSAI ET AL.lectrophoretic mobility shift assay and supershift
ssay
The nuclear extract of C33A cells was purified as
escribed previously (Dignan et al., 1983). For gel shift
ssay, 10 mg of nuclear extracts was incubated with 13
inding buffer (10 mM HEPES, pH 7.9, 50 mM NaCl, 10
M MgCl2, 0.1 mM EDTA, 1 mM DTT, and 5% glycerol), 1
g of poly(dI–dC) (Boehringer-Mannheim, Germany), and
.2 pmol of double-stranded DNA probe with or without
003 excess of unlabeled competitors on ice for 30 min.
NA probe was 59 end-labeled with [g-32P]ATP by T4
NA polynucleotide kinase (Bio-lab, UK). One microgram
f Sp1 or Sp3 antibody (Santa Cruz, CA) was added in
ach supershift assay. Reaction mixtures were analyzed
n a 4% nondenaturing polyacrylamide gel at 340 V.
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